Intelligent Bio Solutions Inc.

Equities

INBS

US36151G6008

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-07-01 pm EDT			5-day change	1st Jan Change
1.84 ^USD	+0.38%		+1.94%	-54.62%

Jun. 18	Intelligent Bio Solutions Inc. Begins Subject Dosing and Sampling for FDA 510(k) Pharmacokinetic (PK) Study for its Intelligent Fingerprinting Drug Screening Technology	CI
Jun. 12	Intelligent Bio Solutions Adds Major European Transport and Infrastructure Solutions Provider to Growing Number of Accounts Adopting Fingerprint Drug Screening Technology	CI

GBS Inc. Announces Resignation of Harry Simeonidis as CEO

November 03, 2021 at 05:01 pm EDT

Harry Simeonidis, who served as CEO of GBS Inc., vacated position prior to Professor Boyages' appointment as Interim CEO and was appointed to the position of President Asia Pacific, Sales and Marketing, effective October 29, 2021.

Latest news about Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. Begins Subject Dosing and Sampling for FDA 510(k) Pharmacokinetic (PK) Study for its Intelligent Fingerprinting Drug Screening Technology	Jun. 18	CI
Intelligent Bio Solutions Adds Major European Transport and Infrastructure Solutions Provider to Growing Number of Accounts Adopting Fingerprint Drug Screening Technology	Jun. 12	CI
Intelligent Bio Solutions Inc. Announces Board Changes	Jun. 07	CI
Intelligent Bio Solutions Starts Subject Screening for Drug Testing System Study	May. 29	MT
Intelligent Bio Solutions Inc. Completes Recruitment and Begins Subject Screening for FDA 510(K) Pharmacokinetic Study	May. 29	CI
Earnings Flash (INBS) INTELLIGENT BIO SOLUTIONS Reports Q3 Revenue $823,800	May. 08	MT
Intelligent Bio Solutions Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	May. 08	CI
Intelligent Bio Solutions Inc. announced that it has received $10.116165 million in funding	Mar. 11	CI
Intelligent Bio Solutions Inc. announced that it expects to receive $10.116165 million in funding	Mar. 07	CI
Top Premarket Decliners	Feb. 12	MT
Top Midday Gainers	Feb. 09	MT
Earnings Flash (INBS) INTELLIGENT BIO SOLUTIONS Reports Q2 Revenue $764,063	Feb. 09	MT
Intelligent Bio Solutions Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 09	CI
Sector Update: Health Care Stocks Advance Late Afternoon	Feb. 02	MT
Sector Update: Health Care Stocks Decline Friday Afternoon	Feb. 02	MT
Top Midday Gainers	Feb. 02	MT
Intelligent Bio Solutions Inc. Provides Unaudited Preliminary Earnings Guidance for the Second Quarter and Six Months Ended December 31, 2023	Feb. 02	CI
Sector Update: Health Care Stocks Stronger Late Afternoon	Jan. 29	MT
Sector Update: Health Care	Jan. 29	MT
Intelligent Bio Solutions Says Fingerprinting Drug Screening System Being Used by UK Timber Processor; Shares Soar	Jan. 29	MT
James Jones & Sons Ltd. Adopts Intelligent Bio Solutions Inc.'s Fingerprint Drug Screening System Across its 25 Sites and 1,300 Employees	Jan. 29	CI
Intelligent Bio Solutions Inc. Announces Selection of the Revolutionary Portable Intelligent Fingerprinting Drug Screening System by Dgp plc	Jan. 22	CI
Intelligent Bio Solutions Receives NATA Accreditation for Its Revolutionary Fingerprint Sweat Drug Screening System	Dec. 19	CI
P&O Ferries, Adopts Fingerprint Drug Screening Solution for On-Board, Random Testing of Seafaring Staff	Dec. 05	CI
Intelligent Bio Solutions Inc. Announces Titan Cranes and Rigging Pty Ltd. Adopts Intelligent Fingerprinting Drug Screening System	Nov. 30	CI

Chart Intelligent Bio Solutions Inc.

Duration

Period

More charts

Company Profile

Intelligent Bio Solutions Inc. is a life sciences company. The Company is engaged in developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It operates through two segments, namely Commercially available Intelligent Fingerprinting Products (IFPG) and Development Stage Saliva Glucose Biosensor Platform (SGBP). Its product portfolio includes a portable drug screening system that works by analyzing fingerprint sweat using a one-time cartridge and portable handheld reader and also includes a development stage range of biosensor- based Point of Care diagnostic tests (POCT) that are developed in the modalities of clinical chemistry, immunology, tumor markers, allergens, and endocrinology. Its product candidate is the Saliva Glucose Biosensor (SGB), a POCT expected to substitute the finger pricking invasive blood glucose monitoring for diabetic patients. Its Biosensor Platform helps to detect multiple biological analytes.

Sector

Biotechnology & Medical Research

Calendar

2024-11-05 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Intelligent Bio Solutions Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.84 USD

Average target price

12 USD

Spread / Average Target

+552.17%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
INTELLIGENT BIO SOLUTIONS INC.	-54.62%	5.74M
EXACT SCIENCES CORPORATION	-41.62%	7.97B
GUARDANT HEALTH, INC.	+5.03%	3.53B
IOVANCE BIOTHERAPEUTICS, INC.	-9.10%	2.16B
BGI GENOMICS CO., LTD.	-27.31%	1.84B
VERACYTE, INC.	-21.96%	1.63B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+6.72%	909M
CAREDX, INC	+24.08%	778M
SEEGENE, INC.	-9.61%	696M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-30.82%	497M

Bio Diagnostics & Testing